Wright Medical Group, Inc. (WMGI), an international orthopedic medical devices company with a focus on the ankle and foot markets, recently announced the commercial launch of Pro-Stim Injectable Inductive Graft. The Pro-Stim graft is a new grafting material, which is either digitally implanted or inserted though a tiny needle. It hardens over time and is gradually replaced by the patients’ new bone.
The Pro-Stim graft catapults on the clinical success of the company’s earlier Pro-Dense material. This product gives medical practitioners the osteo-conductive base material, which is a patented amalgamation of calcium phosphate and calcium sulfate substances. It, however, adds the extra volume of osteo-inductive de-mineralized bone matrix to expedite the recovery process of the patient.
In pre-clinical trials, the Pro-Stim graft showed accelerated healing to autograft bone, which was long considered to be the premier graft. This positive feature is expected to be useful for human usage, particularly to restore skeletal and bone abnormalities. One medical practitioner confirmed that Pro-Stim graft provides doctors with an acceptable alternative to autograft and comes without certain complications.
Pro-Stim graft received the U.S. Food and Drug Administration (FDA) clearance in September 2009. It was gradually released to a group of institutions, over a 13-month period, in order to verify human benefit. Wright Medical expended extra resources to bolster its clinical knowledge ahead of the full commercial release. The company believes that its knowledge gleaned from over 600 cases indicates that Pro-Stim graft will deliver outcomes in consonance with expectations.
Wright Medical Group will immediately make this new product available in the U.S. and in select international markets through its distributor-based and direct sales force. Pro-Stim graft is the most recent product in the company’s Biologics franchise, whose stable of products includes the Xpansion Micrografting System, the Pro-Dense Injectable Regenerative Graft and the Graftjacket Regenerative Tissue Matrix.
WRIGHT MEDICAL (WMGI): Free Stock Analysis Report
Zacks Investment Research
